New therapeutic strategies in the management of systemic sclerosis

被引：47

作者：

Allanore, Yannick ^{[1
]}

Avouac, Jerome ^{[1
]}

Wipff, Julien ^{[1
]}

Kahan, Andre ^{[1
]}

机构：

[1] Univ Paris 05, AP HP, Dept Rheumatol, A Cochin Hosp,Med Fac, F-75014 Paris, France

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2007年 / 8卷 / 05期

关键词：

systemic sclerosis;

D O I：

10.1517/14656566.8.5.607

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The pathogenic process of systemic sclerosis targets the skin and internalorgans, and involves sequential or concomitant abnormalities in blood vessel function, immunity and subsequent fibroblast function. These characteristics are disease specific and may partly explain the unresolved therapeutic strategies that must take into account not only these various biological abnormalities, but also the complexities of the various abnormalities throughout the duration of the disease. However, recent epidemiological data have revealed a decrease in excess mortality, which may be mostly due to the use of cardiovascular drugs. This article deals with present and possible future therapeutic options. Keywords: systemic sclerosis

引用

页码：607 / 615

页数：9

共 74 条

[1]

Allanore Y, 2006, J RHEUMATOL, V33, P2464

[2] Treatment of systemic sclerosis [J].

Allanore, Yannick ;

Kahan, Andre .

JOINT BONE SPINE, 2006, 73 (04) :363-368

[3]

Arnett FC, 2001, ARTHRITIS RHEUM-US, V44, P1359, DOI 10.1002/1529-0131(200106)44:6<1359::AID-ART228>3.0.CO

[4]

2-S

[5] Genetics of scleroderma: update on single nucleotide polymorphism analysis and microarrays [J].

Assassi, S ;

Tan, FK .

CURRENT OPINION IN RHEUMATOLOGY, 2005, 17 (06) :761-767

[6] Systemic sclerosis-associated Sjogren's syndrome and relationship to the limited cutaneous subtype - Results of a prospective study of Sicca syndrome in 133 consecutive patients [J].

Avouac, J. ;

Sordet, C. ;

Depinay, C. ;

Ardizonne, M. ;

Vacher-Lavenu, M. C. ;

Sibilia, J. ;

Kahan, A. ;

Allanore, Y. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (07) :2243-2249

[7] Radiological hand involvement in systemic sclerosis [J].

Avouac, J. ;

Guerini, H. ;

Wipff, J. ;

Assous, N. ;

Chevrot, A. ;

Kahan, A. ;

Allanore, Y. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (08) :1088-1092

[8] Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].

Badesch, DB ;

Tapson, VF ;

McGoon, MD ;

Brundage, BH ;

Rubin, LJ ;

Wigley, FM ;

Rich, S ;

Barst, RJ ;

Barrett, PS ;

Kral, KM ;

Jöbsis, MM ;

Loyd, JE ;

Murali, S ;

Frost, A ;

Girgis, R ;

Bourge, RC ;

Ralph, DD ;

Elliott, CG ;

Hill, NS ;

Langleben, D ;

Schilz, RJ ;

McLaughlin, VV ;

Robbins, IM ;

Groves, BM ;

Shapiro, S ;

Medsger, TA ;

Gaine, SP ;

Horn, E ;

Decker, JC ;

Knobil, K .

ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+

[9]

Baroni SS, 2006, NEW ENGL J MED, V354, P2667

[10] Sitaxsentan therapy for pulmonary arterial hypertension [J].

Barst, RJ ;

Langleben, D ;

Frost, A ;

Horn, EM ;

Oudiz, R ;

Shapiro, S ;

McLaughlin, V ;

Hill, N ;

Tapson, VF ;

Robbins, IM ;

Zwicke, D ;

Duncan, B ;

Dixon, RAF ;

Frumkin, LR .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (04) :441-447

← 1 2 3 4 5 6 7 8 →